---
title: "I-Mab Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026"
description: "I-Mab, a U.S.-based biotech company, has reported progress in the clinical development of its therapy, givastomig, with positive Phase 1b dose escalation data presented at ESMO GI 2025. The company is"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/248953469.md"
published_at: "2025-07-17T11:05:46.000Z"
---

# I-Mab Announces Phase 1b Dose Expansion Progress for Givastomig, Anticipates Topline Readout in Q1 2026

> I-Mab, a U.S.-based biotech company, has reported progress in the clinical development of its therapy, givastomig, with positive Phase 1b dose escalation data presented at ESMO GI 2025. The company is experiencing faster enrollment in the Phase 1b dose expansion cohorts and expects to provide a topline readout in Q1 2026. This follows I-Mab's acquisition of Bridge Health, enhancing givastomig's intellectual property by securing upstream rights and eliminating royalty obligations.

I-Mab, a U.S.-based global biotech company, has announced significant progress in the clinical development of its investigational therapy, givastomig. The company recently presented positive Phase 1b dose escalation data at ESMO GI 2025, which has strengthened their confidence in givastomig’s potential as a best-in-class CLDN18.2-directed therapy for the treatment of gastric cancers and other applications. Following this progress, I-Mab reports faster than anticipated enrollment in the Phase 1b dose expansion cohorts. The company anticipates providing a topline readout of the study in the first quarter of 2026. This development follows I-Mab’s strategic acquisition of Bridge Health, which enhances the intellectual property portfolio of givastomig by securing upstream rights and eliminating royalty obligations related to the CLDN18.2 parental antibody. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-096437), on July 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IMAB.US - I-Mab](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| IHI, IHE, ARKG: Specialty Healthcare ETFs Can Help Boost a Portfolio | Specialty healthcare ETFs can enhance investment portfolios by focusing on distinct sectors like pharmaceuticals, medica | [Link](https://longbridge.com/en/news/276080275.md) |
| A Look At Agree Realty (ADC) Valuation After Raised 2026 Investment Guidance And Dividend Increase | Agree Realty (ADC) has raised its 2026 investment guidance and increased its annual dividend, leading to a positive mark | [Link](https://longbridge.com/en/news/276090924.md) |
| Starting with HyperLiquid: What kind of exchange does RWA really need? | The article discusses the rise of HyperLiquid and Aster in the decentralized exchange (DEX) market, emphasizing that the | [Link](https://longbridge.com/en/news/276022874.md) |
| Touring a 3,000-ton silo expansion | A look at Rockscape Farm’s massive new silo capacity and how it boosts storage and efficiency during harvest season. | [Link](https://longbridge.com/en/news/276076561.md) |
| Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? | Alvotech's stock has seen a significant decline of 64.3% over the past year, currently priced at US$4.64. Despite recent | [Link](https://longbridge.com/en/news/276074198.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
